Oncotarget

BUFFALO, NY – October 14, 2026 – A new #research paper was #published in Volume 17 of #Oncotarget on October 12, 2026, titled “Integrative pan-cancer analysis of AKT1 and structure-based drug design by buckwheat derived compounds.” The study examined the role of AKT1 across 33 cancer types and identified fagopyrine, a naturally occurring compound found in buckwheat, as a potential starting point f...

Cancer cells often survive by disrupting the molecular pathways that normally eliminate damaged or abnormal cells. One of these pathways is apoptosis, a tightly controlled form of programmed cell death. New research suggests that an apoptosis-related receptor called TRAIL-R2 is frequently reduced in breast tumors and that epigenetic changes affecting its gene could contribute to this loss of expre...

BUFFALO, NY – September 28, 2026 – A new #editorial was #published in Volume 17 of Oncotarget on September 23, 2026, titled “Gut feeling: Microbes at the heart of cancer therapy.” The article examines how the human microbiome may influence cancer development, treatment response and emerging precision-oncology strategies. The editorial was led by first author Uzma Saqib, with Krishnan Hajela servin...

Cancer cells do not grow in isolation. Their ability to survive and form tumors depends partly on how they interact with immune cells in the surrounding tumor microenvironment. Melanoma is particularly responsive to immune-based mechanisms, making it important to understand the molecular processes that allow melanoma cells to limit or escape antitumor immune responses. A research paper published i...

BUFFALO, NY – September 17, 2026 – A new #commentary was #published in Volume 17 of Oncotarget on September 11, 2026, titled “Are both COVID-19 and COVID-19 vaccines associated with cancer?” The paper was authored by Raphael Lataster, an independent researcher at the University of Sydney, and responds to a recent Oncotarget review by Charlotte Kuperwasser and Wafik S. El-Deiry examining published...

BUFFALO, NY – September 9, 2026 – A new #review was #published in Volume 17 of Oncotarget on September 8, 2026, titled “Re-expression of MHC-I to treat CNS cancers.” The review examines emerging strategies to restore major histocompatibility complex class I (MHC-I) expression in cancers of the central nervous system (CNS), with the goal of making these tumors more visible and vulnerable to immune...

Head and neck squamous cell carcinoma (HNSCC) can return even after patients complete surgery, radiation, chemotherapy, or combinations of these treatments. Preventing recurrence therefore remains an important challenge in head and neck cancer care. Human papillomavirus (HPV), particularly HPV type 16, is also an established cause of a subset of these cancers, especially oropharyngeal squamous cel...

BUFFALO, NY - September 8, 2026 – Oncotarget is proud to support the WIN 2026 Symposium, organized by the Worldwide Innovative Networking (WIN) Consortium, taking place October 2–3, 2026, at the Rhode Island Convention Center in Providence. The two-day symposium, themed “Precision Oncology: Innovation and Equity Across the Globe,” will bring together researchers, clinicians, healthcare professiona...

BUFFALO, NY – September 1, 2026 – A new #review was published in Volume 17 of Oncotarget on August 28, 2026, titled “Emerging biomedical imaging applications of tumor-derived extracellular vesicles for premetastatic niche detection: Biological rationale, engineering strategies, and translational challenges.” The review was led by first author Omkar Dhaygude, who is affiliated with Johns Hopkins Un...

BUFFALO, NY – August 31, 2026 – A new #editorial was published in Volume 17 of Oncotarget on June 8, 2026, titled “Tumor infiltrating lymphocyte (TIL) therapy for treating the solid tumors: Challenges and future perspectives.” The editorial was led by first and corresponding author Bhartendra Sharma from Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, India, along...

BUFFALO, NY – August 28, 2026 – A new #research paper was published in Volume 17 of Oncotarget on August 19, 2026, titled “Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine.” The study was led by first author Kelly Crane from the Department of Urology at SUNY Upstate Medical University. The corresponding author is K. R. Seetharam Bhat, who is aff...

BUFFALO, NY – August 25, 2026 – A new precision oncology paper was #published in Volume 17 of Oncotarget on August 14, 2026, titled “Systematic methodological flaws in DNA contamination assessment of mRNA vaccines: A critical analysis of Achs et al. (2025).” The article was led by first and corresponding author Kevin McKernan from Medicinal Genomics, Beverly, Massachusetts, along with co-authors D...

Pancreatic cancer remains one of the most difficult cancers to treat, in part because mutations in the KRAS gene are extraordinarily common in pancreatic ductal adenocarcinoma (PDAC). These mutations keep growth-promoting signals switched on, allowing cancer cells to proliferate and survive. Although drugs targeting certain KRAS mutations have emerged in recent years, they work against only a subs...

BUFFALO, NY – August 10, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on August 7, 2026, titled “Delayed growth of SK-ES-1 Ewing sarcoma tumor xenografts is associated with reduced Trk and IGF1R pathway markers.” The study was led by first author Bruna Almeida dos Santos and corresponding author Caroline Brunetto de Farias, primarily affiliated with the Federal University...

Colorectal cancer does not develop in isolation. Cancer cells exist within a complex tumor microenvironment made up of fibroblasts, immune cells, blood vessels, and extracellular matrix. Increasing evidence suggests that these surrounding cells and structures can influence whether tumors grow, regress, or evade the immune system. A research paper published in Volume 17 of Oncotarget, titled “Micro...

Nutrition plays a critical role in cancer care, yet it is often overlooked. Many patients experience weight loss, muscle wasting, treatment-related side effects, and changes in appetite that can affect their ability to tolerate therapy and maintain quality of life. Although nutrition specialists can help manage these challenges, access to specialized nutritional care remains limited in many health...

BUFFALO, NY – July 22, 2026 – A new #PrecisionOncology paper was #Published in Volume 17 of Oncotarget on July 21, 2026, titled “WIN-MTB-2024017 – WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.” The study was led by Oncotarget Editor-in-Chief, Dr. Wafik S. El-Deiry, from the Worldwide Innovative Network (WIN) Association – WIN Consortium and Legorreta...

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. Although many GISTs can be effectively treated with targeted therapies, their response to treatment depends largely on the specific genetic alterations driving tumor growth. Advances in molecular testing have transformed the management of these tumors, allowing clinicians to tailor treatment base...

BUFFALO, NY – July 6, 2026 – A new #casereport was #published in Volume 17 of Oncotarget on July 2, 2026, titled “Renal oncocytoma: Α case report and literature review.” The study was led by first and corresponding author Areti Kalfoutzou from the Second Propaedeutic Department of Internal Medicine, Attikon General Hospital, National and Kapodistrian University of Athens, Greece. Renal oncocytoma...

Multiple myeloma is the second most common blood cancer in the United States and has long been considered a difficult disease to treat. For decades, treatment options were limited, and survival remained poor. However, the therapeutic landscape has changed dramatically over the past several decades with the introduction of stem cell transplantation, targeted drugs, immunotherapies, and more recentl...

BUFFALO, NY – June 24, 2026 – A new research paper was published in Volume 17 of Oncotarget on June 9, 2026, titled “TRAIL-R2 in the shadows: Epigenetic silencing and clinical implications in breast cancer.” The study was led by first author Nuzhat Khursheed from the University of Kashmir and corresponding authors Asia Asiaf from the Central University of Kashmir and Showkat Ahmad Ganie from the U...

BUFFALO, NY – June 17, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on June 8, 2026, titled “DHHC3 interferes with antitumor immunity in melanoma cells.” The study was led by first author and corresponding author Chandan Sharma and corresponding author Martin E. Hemler from the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute. Melanoma is o...

Prostate cancer is the most commonly diagnosed cancer among men and remains a leading cause of cancer-related death worldwide. While age, family history, and genetics are well-established risk factors, researchers have increasingly focused on the role of metabolic health in prostate cancer progression. Obesity, insulin resistance, type 2 diabetes, and chronic inflammation have all been associated...

BUFFALO, NY – June 15, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on June 5, 2026, titled “A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence.” The study was led by first author Emily Bivens and corresponding author Mayumi Nakagawa fro...

BUFFALO, NY – June 8, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on June 3, 2026, titled “The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation.” The study was led by first author Kweku Ofosu-Asante and corresponding author Nazarius S. Lamango from the Florida A&M University College of Pharmacy and Pharmaceutical S...